Editor’s Note: Although the following article discusses competitive bidding with respect to Medicare Part D, a key issue relevant to DME is also discussed, the dangers of price controls.
From: Wall Street Journal
Price controls on Part D drugs would cripple medical innovation and undermine a successful federal entitlement program.
By TOMAS J. PHILIPSON
Medicare Part D, the prescription-drug benefit program for seniors, has cost the federal government considerably less than was initially estimated. It’s also overwhelmingly popular among beneficiaries. But in Washington, Part D is now a prime target for overhaul. In the heat of debate over the debt ceiling, President …